LLG783 in PAD and Intermittent Claudication

Phase 2, randomised, double-blind trial in peripheral artery disease (PAD) and intermittent claudication (IC) comparing LLG783 with Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events (AEs), Drug-related AEs, Serious Adverse Events (SAEs) and Deaths up to 32 Weeks and Change From Baseline in Maximum Walking Distance (MWD) as Assessed by 6-minute Walk Test (6MWT). Started Sep 2017; status: completed.